Streetbeat News

Price Targets

SKWD

Raymond James analyst C. Gregory Peters maintains a Strong Buy rating on Skyward Specialty (NASDAQ:SKWD) and raises the price target from $25 to $28.

Portfolio Pulse from richadhand@benzinga.com

May 25, 2023 | 11:13 am

NVDA

Raymond James analyst Chris Caso maintains a Strong Buy rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $290 to $450.

Portfolio Pulse from richadhand@benzinga.com

May 25, 2023 | 11:12 am

AEO

American Eagle Outfitters reported Q1 earnings in line with market estimates but lowered its full-year revenue outlook. The company's shares dropped 18.9% in pre-market trading. Telsey Advisory Group and Barclays cut their price targets on AEO following the earnings announcement.

Portfolio Pulse from Lisa Levin

May 25, 2023 | 11:11 am

ARAV

EF Hutton analyst Tony Butler reiterates a Buy rating on Aravive (NASDAQ:ARAV) and maintains a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

May 25, 2023 | 11:10 am

BNGO

EF Hutton initiates coverage on Bionano Genomics (NASDAQ:BNGO) with a Buy rating and announces a price target of $1.75.

Portfolio Pulse from richadhand@benzinga.com

May 25, 2023 | 11:09 am

KSS

Baird analyst Mark Altschwager maintains an Outperform rating on Kohl's (NYSE:KSS) but lowers the price target from $35 to $30.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 11:08 am

NVDA

JP Morgan analyst Harlan Sur maintains an Overweight rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $250 to $500.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 11:08 am

BMEA

EF Hutton analyst Michael King assumes Biomea Fusion (NASDAQ:BMEA) with a Buy rating and announces a price target of $32.

Portfolio Pulse from richadhand@benzinga.com

May 25, 2023 | 11:07 am

TMO

JP Morgan analyst Tycho Peterson maintains an Overweight rating on Thermo Fisher Scientific (NYSE:TMO) and lowers the price target from $675 to $660.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 11:07 am

JSPR

EF Hutton analyst Michael King assumes coverage of Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and announces a price target of $6.85.

Portfolio Pulse from richadhand@benzinga.com

May 25, 2023 | 11:07 am